Development of a protocol for assessment of suicide risk in patients with head and neck cancer

a.sfakia shared this article with you from Inoreader Development of a protocol for assessment of suicide risk in patients with head and neck cancer Via Oral and Maxillofacial Surgery Head and neck cancer (HNC) is the 7th most prevalent cancer globally, with an increasing incidence in recent years which is expected to continue. For many patients, the experience of receiving a diagnosis of HNC and subsequent treatment is disturbing and traumatic. Evidence suggests that HNC patients have a significantly increased risk of suicide compared with other cancer patients and the general population. Multiple social and medical factors may increase suicide risk in an individual, and include smoking and alcohol misuse. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Adjuvant management of locally advanced oral squamous cell carcinoma – real-world challenges and opportunities

a.sfakia shared this article with you from Inoreader Adjuvant management of locally advanced oral squamous cell carcinoma – real-world challenges and opportunities Via Oral and Maxillofacial Surgery Patients with locally advanced oral squamous cell cancer (LAOSCC) are treated with adjuvant radiotherapy (RT) or chemoradiotherapy (CRT) following surgical ablation. This depends on the pathological risk factors and aims to reduce the risk of local recurrence and improve survival. Delivery of these aggressive treatments is, however, challenging particularly following major surgery. To inform the adaptations necessary to deliver gold-standard therapy, we aimed to describe real-world delivery of multimodality treatment in LAOSCC, in a UK population with high levels of disease incidence and low socioeconomic status. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Challenges and outcomes in establishing a sentinel lymph node biopsy service for oral squamous cell carcinoma in a regional district specialist hospital

a.sfakia shared this article with you from Inoreader Challenges and outcomes in establishing a sentinel lymph node biopsy service for oral squamous cell carcinoma in a regional district specialist hospital Via Oral and Maxillofacial Surgery UK national guidelines in 2016 recommended that sentinel lymph node biopsy (SLNB) should be offered to patients with early oral squamous cell carcinoma (OSCC). We review the establishment of an OSCC SLNB service with specific consideration to resources, service implications and patient outcomes. A review of processes was performed to identify key stages in establishing the service, and subsequently a retrospective cohort study consisting of 46 consecutive patients with T1/T2 N0 OSCC was undertaken. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Signs and Symptoms of Ocular Surface Disease: The Reasons for Patient Dissatisfaction with Glaucoma Treatments

a.sfakia shared this article with you from Inoreader Message: RAPID COMMUNICATION Signs and Symptoms of Ocular Surface Disease: The Reasons for Patient Dissatisfaction with Glaucoma Treatments Abstract Fulltext Metrics Get Permission Cite this article Authors Stalmans I, Lemij H, Clarke J, Baudouin C Received 6 July 2020 Accepted for publication 6 October 2020 Published 30 October 2020 Volume 2020:14 Pages 3675—3680 DOI https://doi.org/10.2147/OPTH.S269586 Checked for plagiarism Yes Review by Single anonymous peer review Peer reviewer comments 4 Editor who approved publication: Dr Scott Fraser Ingeborg Stalmans,1 Hans Lemij,2 Jonathan Clarke,3 Christophe Baudouin4 On behalf of the GOAL study group 1Department of Ophthalmology, UZ Leuven, Leuven, Belgium; 2Glaucoma Service, Rotterdam Eye Hospital, Rotterdam, the Netherlands; 3NIHR Biomedical Research Centre - Moorfields Eye Hospital, NHS Foundation Trust and UCL Institute of Ophthalmology, London, UK; 4Ophthalmology Unit, Quinze-Vingts National Hospital and Vision Institute, IHU ForeSight, Sorbonne University, Paris, France Correspondence: Christophe Baudouin Ophthalmology Unit, Quinze-Vingts National Hospital and Vision Institute, IHU ForeSight, Sorbonne University, Paris, France Email cbaudouin@15-20.fr Abstract: Ocular Surface Disease (OSD) and hyperemia are the most common adverse events of topical ocular medications. While active compounds may cause allergic reactions or irritation, preservatives, which are intended to prevent bacterial growth, are toxic as well. Therefore, the most recent glaucoma medications no longer contain preservatives. Despite this, local tolerability may still impact treatment compliance and patient quality of life. We conducted an observational, multi-center, international, cross-sectional study in 793 treated and stabilized glaucoma patients to assess patient satisfaction and local tolerability of their treatment. The vast majority (93.7%) of patients was satisfied or very satisfied with their treatment in terms of tolerability and only 6.3% were dissatisfied. However, ophthalmological examination showed a high frequency of ocular signs: conjunctival hyperemia (32%), OSD (42.5%) and positive conjunctival fluorescein staining (10.3%). Additionally, patie nts reported symptoms upon instillation (31.4%) and between instillations (57.3%); 25.1% of patients were using tear substitutes. All signs and symptoms were significantly (p< 0.001) associated with patient dissatisfaction. A logistic regression model indicated that dissatisfaction was higher in patients with symptoms upon instillation and in those using tear substitutes (OR: 3.03 and 4.63, respectively). The mean patient tolerability score to treatment was 82.7± 16.1 on a 100-point visual analogue scale. In conclusion, even if patients may be highly satisfied with their current treatment, most of them present ocular signs and symptoms. A treatment change should be considered in case of clinical signs or patient-reported symptoms. Keywords: glaucoma, tolerance, preservatives, tear substitutes, patient satisfaction, ocular surface disease Signs and Symptoms of Ocular Surface Disease: The Reasons for Patient Dissatisfaction with Glaucoma Treatments Via Clinical Ophthalmology View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Solitary Plasmacytoma of the Frontal Bone.

a.sfakia shared this article with you from Inoreader Solitary Plasmacytoma of the Frontal Bone. Via pubmed: "j korean neurosurg ... Related Articles Solitary Plasmacytoma of the Frontal Bone. J Korean Neurosurg Soc. 2020 Oct 28;: Authors: Peker BC, Ataızı ZS, Ozbek Z Abstract Extramedullary plasmacytoma and solitary plasmacytoma are localized neoplasms. Solitary plasmacytoma of bone consists about 4% of malignant plasma cell tumors. A plasmacytoma involving the frontal bone is unusual, and a limited number of cases have been reported. We present a rare case of a solitary plasmacytoma of the frontal bone manifesting as a forehead lump. PMID: 33108859 [PubMed - as supplied by publisher] View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Effects of HER family-targeting tyrosine kinase inhibitors on antibody-dependent cell-mediated cytotoxicity in HER2-expressing breast cancer

a.sfakia shared this article with you from Inoreader Effects of HER family-targeting tyrosine kinase inhibitors on antibody-dependent cell-mediated cytotoxicity in HER2-expressing breast cancer Via Clinical Cancer Research Online First Articles Purpose: Antibody-dependent cell-mediated cytotoxicity (ADCC) is one mechanism of action of the monoclonal antibody (mAb) therapies trastuzumab and pertuzumab. Tyrosine kinase inhibitors (TKIs) like lapatinib may have added therapeutic value in combination with mAbs through enhanced ADCC activity. Using clinical data, we examined the impact of lapatinib on HER2/EGFR expression levels and NK cell gene signatures. We investigated the ability of three TKIs (lapatinib, afatinib, neratinib) to alter HER2/immune-related protein levels in pre-clinical models of HER2+ and HER2-low breast cancer, and the subsequent effects on trastuzumab/pertuzumab-mediated ADCC. Experimental Design: Pre-clinical studies (proliferation assays, Western blot, high content analysis, flow cytometry) employed HER2+ (SKBR3, HCC1954) and HER2-low (MCF-7, T47D, CAMA-1, CAL-51) breast cancer cell lines. NCT00524303 provided RPPA-determined protein levels of HER2/pHER2/EGFR/pEGFR. RNA-based NK cell gene signatures (Cibersort/MCP-counter) post-neo-adjuvant anti-HER2 therapy were assessed (NCT00769470/NCT01485926). ADCC assays utilized flow-cytometry-based protocols. Results: Lapatinib significantly increased membrane HER2 levels, while afatinib and neratinib significantly decreased levels in all pre-clinical models. Single agent lapatinib increased HER2 or EGFR levels in 10/11 (91%) tumor samples. NK cell signatures increased post-therapy (p=0.03) and associated with trastuzumab response (p=0.01). TKI treatment altered mAb-induced NK cell-mediated ADCC in vitro but it did not consistently correlate with HER2 expression in HER2+ or HER2-low models. The ADCC response to trastuzumab and pertuzumab combined did not exceed either mAb alone. Conclusions: TKIs differentially alter tumor cell phenotype which can impact NK cell-mediated response to co-administered antibody therapies. mAb-induced ADCC response is relevant when rationalizing combinations for clinical investigation.< /p> View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Mutational Landscape and Tumor Burden Assessed by Cell-Free DNA in Diffuse Large B-Cell Lymphoma in a Population-based Study

a.sfakia shared this article with you from Inoreader Mutational Landscape and Tumor Burden Assessed by Cell-Free DNA in Diffuse Large B-Cell Lymphoma in a Population-based Study Via Clinical Cancer Research Online First Articles Purpose: We analyzed the utility of cfDNA in a prospective population-based cohort to determine the mutational profile, assess tumor burden, and estimate its impact in response rate and outcome in patients with DLBCL. Experimental Design: One-hundred patients were diagnosed with DLBCL during the study period. Mutational status of 112 genes was studied in cfDNA by targeted next-generation sequencing. Paired formalin-fixed paraffin-embedded samples and volumetric PET/CT were assessed when available. Results: Appropriate cfDNA to perform the analyses was obtained in 79/100 cases. At least one mutation could be detected in 69/79 cases (87%). The sensitivity of cfDNA to detect the mutations was 68% (95% CI: 56.2-78.7). The mutational landscape found in cfDNA samples was highly consistent with that shown in the tissue and allowed genetic classification in 43% of the cases. A higher amount of ctDNA significantly correlated with clinical parameters related to tumor burden (elevated LDH and β2-microglobulin serum levels, advanced stage, and high-risk IPI) and total metabolic tumor volume assessed by PET/CT. In patients treated with curative intent, high ctDNA levels (>2.5 log hGE/mL) were associated with lower complete response (65% vs. 96%, P<0.004), shorter progression-free survival (65% vs. 85%, P=0.038) and overall survival (73% vs. 100%, P=0.007) at 2 years, although it did not maintain prognostic value in multivariate analyses. Conclusions: In a population-based prospective DLBCL series, cfDNA resulted an alternative source to estimate tumor burden and to determine the tumor mutational profile and genetic classification, which have prognostic implications and may contribute to a future tailored treatment. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.